2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (21 Days): Results From the Telavancin Observational Use Registry (TOUR™)

摘要

BackgroundTelavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive organisms, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. New onset or worsening renal impairment was observed in phase 3 clinical trials. This analysis was conducted to better understand changes in renal function from real-world experience during prolonged TLV therapy.